Pharmacodynamics of oritavancin (LY333328) in a neutropenic-mouse thigh model of Staphylococcus aureus infection
about
Oritavancin: A New Lipoglycopeptide Antibiotic in the Treatment of Gram-Positive InfectionsProfile of oritavancin and its potential in the treatment of acute bacterial skin structure infectionsPharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose.Exploring the collaboration between antibiotics and the immune response in the treatment of acute, self-limiting infectionsPharmacokinetic-pharmacodynamic relationships describing the efficacy of oritavancin in patients with Staphylococcus aureus bacteremia.Current and novel antibiotics against resistant Gram-positive bacteriaComparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial.Oritavancin and tigecycline: investigational antimicrobials for multidrug-resistant bacteria.In Vivo Assessment of Phage and Linezolid Based Implant Coatings for Treatment of Methicillin Resistant S. aureus (MRSA) Mediated Orthopaedic Device Related Infections.Oritavancin: a new avenue for resistant Gram-positive bacteria.Oritavancin--an investigational glycopeptide antibiotic.Investigational treatments for postoperative surgical site infections.Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections.Pharmacologic treatment options for nosocomial pneumonia involving methicillin-resistant Staphylococcus aureus.Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthraxOritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogens.Oritavancin: a potential weapon in the battle against serious Gram-positive pathogens.Current challenges in treating MRSA: what are the options?Vancomycin resistance: are there better glycopeptides coming?Pharmacodynamic functions: a multiparameter approach to the design of antibiotic treatment regimens.A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.Current and prospective treatments for multidrug-resistant gram-positive infections.New antibiotics for bad bugs: where are we?Oritavancin: A Long-Half-Life Lipoglycopeptide.Dalbavancin and Oritavancin: An Innovative Approach to the Treatment of Gram-Positive Infections.Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.Oritavancin: a long-acting antibacterial lipoglycopeptide.Comparative Pharmacodynamics of Telavancin and Vancomycin in the Neutropenic Murine Thigh and Lung Infection Models against Staphylococcus aureus.Dosing strategies to optimize currently available anti-MRSA treatment options (Part 1: IV options).Pharmacodynamic model to describe the concentration-dependent selection of cefotaxime-resistant Escherichia coli.Oritavancin Pharmacokinetics and Bone Penetration in Rabbits.Pharmacodynamics of teicoplanin against MRSA.Pharmacodynamics of a simulated single 1,200-milligram dose of oritavancin in an in vitro pharmacokinetic/pharmacodynamic model of methicillin-resistant staphylococcus aureus infection.Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.Update on prevalence and treatment of methicillin-resistant Staphylococcus aureus infections.Pharmacodynamics of non-replicating viruses, bacteriocins and lysins.
P2860
Q26772897-724BD19B-38F5-4720-884A-078CEF5BA511Q26799701-6F88EA64-C3C3-4F69-85F3-45029CAB4EB5Q33554567-2B81BE64-32D5-4949-ABA6-26C8274DD391Q33767602-E8641EA8-6820-4E9C-8301-6ADB5B0D402EQ34509676-C9829527-8FB8-4BA1-8D54-C2AB89868C4CQ35026521-5AAF8169-9104-40FF-AA6A-B0FA1904114AQ35065786-21A32B73-E6E4-47BB-8916-406D0D77D63BQ35637071-85E28721-079E-44C6-97DF-C6CF0B080C22Q36059113-214CE10E-59C0-4BA0-99F6-8977919F36EEQ36162339-DE90498D-5A93-4916-8903-788C36367C48Q36426011-649D304E-6B98-4B27-927E-2236120B0638Q36715742-C3D4740A-78BC-4E1E-A280-8E11CCDFA566Q36718474-67FC0A7E-22D9-4C6D-89F0-A837849C3FC4Q36735202-58379801-6A97-4163-BAF1-131F6F0C5E79Q36870766-1B08710B-49A1-4802-B86E-5CAD4252ECC4Q37071199-711FFC91-A832-44AA-B9BA-AD6DF737D6E2Q37174100-1E011149-CAB9-422D-8B70-710A5BC9BE6BQ37291338-FFD22156-247B-449C-BF32-166076141B1DQ37340562-E987FA65-380F-488B-9850-CAF35C83CCC7Q37568933-4ECB3F31-F5D8-4E98-8239-875D883E51ACQ37661510-D719A9F5-7489-42C7-85A4-A734ADC3D9B8Q38123255-E0D34B24-D5E5-4568-B9F5-ED725EB00490Q38132217-1F5847A6-E3D9-488A-9B9E-83723725F398Q38434265-9EF552F9-EB30-413F-BB41-FF2F4166AB88Q38615330-ADB5AB07-0CA4-4615-AFCA-6186758CA95EQ38646905-E9810BF3-0440-4DCB-AD1C-5C03E88FFE14Q38830176-95A9AEC2-B8AB-4F1A-BBD4-4BDC9B7E09D8Q38833633-CAA60B52-7E52-442F-B9A5-1A75981A66A4Q38907793-8C4B016F-E0DB-485B-B303-607F565A73F5Q40666822-C4A405F9-31EA-49DA-9A2E-3181ACA9B8A9Q41073732-234155F4-622A-443D-B88A-BBC57E208802Q41992893-352324AE-E0BE-48E9-A405-00F4F2715BCFQ42530056-54C4DAFD-C6D5-4874-914E-7EB71774E55BQ43834023-6DF100E7-9633-4850-92C3-556B5484153DQ46274310-E0C25D6C-0696-462F-AD69-619721BFF84AQ51932254-4D0BD516-E785-4215-8452-84FD11870470
P2860
Pharmacodynamics of oritavancin (LY333328) in a neutropenic-mouse thigh model of Staphylococcus aureus infection
description
2003 nî lūn-bûn
@nan
2003 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Pharmacodynamics of oritavanci ...... taphylococcus aureus infection
@ast
Pharmacodynamics of oritavanci ...... taphylococcus aureus infection
@en
Pharmacodynamics of oritavancin
@nl
type
label
Pharmacodynamics of oritavanci ...... taphylococcus aureus infection
@ast
Pharmacodynamics of oritavanci ...... taphylococcus aureus infection
@en
Pharmacodynamics of oritavancin
@nl
prefLabel
Pharmacodynamics of oritavanci ...... taphylococcus aureus infection
@ast
Pharmacodynamics of oritavanci ...... taphylococcus aureus infection
@en
Pharmacodynamics of oritavancin
@nl
P2093
P2860
P1476
Pharmacodynamics of oritavanci ...... taphylococcus aureus infection
@en
P2093
Carole J Boylan
Diane L Phillips
Kristina Campanale
Michael L Zeckel
Philip W Iversen
Thomas R Parr
P2860
P304
P356
10.1128/AAC.47.5.1700-1706.2003
P407
P577
2003-05-01T00:00:00Z